Vistagen Appoints Paul Edick to its Board of Directors
Paul R. Edick was appointed to Vistagen Therapeutics' Board of Directors on October 27, 202515.
Following his appointment, Vistagen's Board consists of seven directors26.
Edick will serve on both the Audit and Compensation Committees127.
Mr. Edick brings extensive experience as the former Chairman and CEO of Xeris Pharmaceuticals and has held leadership roles at multiple other pharmaceutical companies including Durata Therapeutics, Ganic Pharmaceuticals, and MedPointe Healthcare2.
He has significant board experience, having served on the boards of Milestone Pharmaceuticals, Iterum Therapeutics, Neos Therapeutics, and others2.
His industry experience is expected to support Vistagen's strategic growth and governance as the company advances its neuroscience-focused clinical programs13.
Upon joining, Edick received stock options under Vistagen’s Amended and Restated 2019 Equity Incentive Plan8.
Edick’s appointment follows the retirement of Dr. Jerry Gin from the Board1.
Sources:
1. https://www.tipranks.com/news/company-announcements/vistagen-therapeutics-appoints-paul-r-edick-to-board
2. https://www.marketscreener.com/news/vistagen-appoints-paul-edick-to-its-board-of-directors-audit-committee-and-the-compensation-committ-ce7d5dd2db8fff27
3. https://www.nasdaq.com/press-release/vistagen-appoints-paul-edick-its-board-directors-2025-10-29
5. https://www.stockinsights.ai/us/VTGN/8-K/management-changes-20251029-9d9
6. https://www.barchart.com/story/news/35758766/vistagen-appoints-paul-edick-to-its-board-of-directors
7. https://www.bioworld.com/articles/725694-appointments-and-advancements-for-oct-30-2025
8. https://www.sec.gov/Archives/edgar/data/0001411685/000162828025047188/vtgn-20251027.htm